Iradimed Corporation (NASDAQ:IRMD) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in shares of Iradimed Corporation (NASDAQ:IRMD) by 39.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,246 shares of the medical equipment provider’s stock after purchasing an additional 4,599 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.13% of Iradimed worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Los Angeles Capital Management LLC raised its holdings in shares of Iradimed by 0.5% during the third quarter. Los Angeles Capital Management LLC now owns 53,301 shares of the medical equipment provider’s stock worth $2,365,000 after purchasing an additional 279 shares during the last quarter. Riverwater Partners LLC raised its holdings in shares of Iradimed by 2.5% during the fourth quarter. Riverwater Partners LLC now owns 11,931 shares of the medical equipment provider’s stock worth $566,000 after purchasing an additional 295 shares during the last quarter. Copeland Capital Management LLC purchased a new position in shares of Iradimed during the third quarter worth $30,000. Gladius Capital Management LP purchased a new position in shares of Iradimed during the third quarter worth $36,000. Finally, Strs Ohio raised its holdings in shares of Iradimed by 8.5% during the third quarter. Strs Ohio now owns 12,800 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the subject of several recent research reports. Roth Mkm reissued a “buy” rating and set a $65.00 target price on shares of Iradimed in a report on Monday. Singular Research reaffirmed a “buy” rating on shares of Iradimed in a report on Monday, April 1st.

Iradimed Stock Performance

IRMD opened at $42.44 on Thursday. Iradimed Corporation has a fifty-two week low of $36.12 and a fifty-two week high of $51.04. The company has a fifty day moving average of $42.92 and a two-hundred day moving average of $43.02. The stock has a market capitalization of $537.46 million, a price-to-earnings ratio of 31.21 and a beta of 0.82.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01). Iradimed had a net margin of 26.22% and a return on equity of 24.62%. The firm had revenue of $17.45 million during the quarter. On average, equities research analysts forecast that Iradimed Corporation will post 1.35 earnings per share for the current year.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.